View of Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists

Return to Article Details Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists Download Download PDF